Ergotamine Tartrate 2 mg/Caffeine 100 mg/Metoclopramide HCl 10 mg Suppositories

This compounded medication combines Ergotamine Tartrate 2 mg, Caffeine 100 mg, and Metoclopramide HCl 10 mg in a suppository form. It is designed to provide relief for patients experiencing severe migraine attacks, particularly when oral administration is not feasible due to nausea or vomiting.

Ergotamine Tartrate is an ergot alkaloid that works by constricting blood vessels in the brain, helping to alleviate the throbbing pain associated with migraines. Caffeine enhances the absorption and effectiveness of Ergotamine, providing a synergistic effect that can improve symptom relief. Metoclopramide HCl is included for its antiemetic properties; it helps to prevent nausea and vomiting, which are common symptoms during migraine episodes, and also promotes gastric emptying.

The suppository form of this medication allows for rapid absorption through the rectal mucosa, bypassing the gastrointestinal tract where absorption might be compromised due to vomiting. This route is particularly beneficial for patients who cannot retain oral medications. By combining these three agents, the formulation aims to address multiple aspects of migraine symptoms simultaneously, offering comprehensive relief.

For patients, it is important to use this medication exactly as prescribed by your healthcare provider. Insert the suppository rectally as directed, usually at the first sign of a migraine attack. Do not exceed the recommended dosage, as overuse of ergotamine-containing products can lead to serious side effects. Common side effects may include dizziness, nausea, or abdominal discomfort. If you experience any severe reactions or if your symptoms persist, contact your healthcare provider promptly.

Prescribers should be aware of the contraindications associated with ergotamine-containing products. This medication is not suitable for patients with peripheral vascular disease, coronary heart disease, hypertension, impaired hepatic or renal function, or who are pregnant or breastfeeding. Caution is advised when prescribing to patients taking other medications that may interact with ergotamine, caffeine, or metoclopramide. Monitoring for signs of ergotism or serotonin syndrome is recommended.

If you have any questions about this compounded medication or its use, please reach out to us. We are here to provide further information and support to ensure appropriate treatment.

Ergotamine Tartrate 2 mg/Caffeine 100 mg/Metoclopramide HCl 10 mg suppositories are a compounded formulation designed to treat migraine headaches by combining the vasoconstrictive properties of ergotamine, the central nervous system stimulant effects of caffeine, and the antiemetic and prokinetic actions of metoclopramide.

When considering the use of this formulation, it is crucial to be aware of potential drug interactions that may affect its safety and efficacy. Ergotamine, a potent vasoconstrictor, can interact with other vasoconstrictive agents, such as triptans, leading to an increased risk of severe vasospastic reactions. Therefore, concurrent use with triptans should be avoided, and a minimum of 24 hours should elapse between the use of ergotamine and any triptan medication.

Caffeine, a central nervous system stimulant, can interact with other stimulants, potentially leading to increased heart rate, elevated blood pressure, and heightened anxiety. Patients should be advised to limit the intake of other caffeine-containing products, such as coffee, tea, and certain sodas, to avoid excessive stimulation and potential cardiovascular effects.

Metoclopramide, a dopamine receptor antagonist, can interact with medications that also affect dopamine pathways, such as antipsychotics, leading to an increased risk of extrapyramidal symptoms or tardive dyskinesia. Additionally, metoclopramide can enhance the sedative effects of central nervous system depressants, such as benzodiazepines, opioids, and alcohol, necessitating caution and possible dose adjustments when these agents are used concurrently.

Patients with a history of cardiovascular disease, hypertension, or peripheral vascular disorders should use this formulation with caution due to the vasoconstrictive effects of ergotamine. Furthermore, the use of ergotamine is contraindicated in patients taking potent CYP3A4 inhibitors, such as certain antifungals and protease inhibitors, due to the risk of ergot toxicity.

For prescribers, it is essential to review the patient's current medication regimen and medical history to identify any potential interactions or contraindications. Monitoring for adverse effects, such as increased blood pressure, chest pain, or signs of serotonin syndrome, is recommended, especially when initiating therapy or adjusting doses.

If you have any questions or require further information regarding this formulation and its potential interactions, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to assist you in ensuring appropriate treatment for your patients.

Ergotamine Tartrate 2 mg/Caffeine 100 mg/Metoclopramide HCl 10 mg suppositories are a compounded formulation designed to provide relief from migraine headaches and associated symptoms. This combination therapy leverages the synergistic effects of its active ingredients to target multiple pathways involved in migraine pathophysiology, offering a comprehensive approach to treatment.

Ergotamine Tartrate is an ergot alkaloid that works primarily by constricting blood vessels in the brain. During a migraine attack, blood vessels in the brain can become dilated, leading to the characteristic throbbing pain. Ergotamine Tartrate helps to counteract this dilation, thereby reducing headache intensity. By acting on serotonin receptors, it also modulates neurotransmitter activity, which can further alleviate migraine symptoms.

Caffeine, a central nervous system stimulant, is included in the formulation to enhance the vasoconstrictive effects of Ergotamine Tartrate. Additionally, caffeine itself can provide mild analgesic effects and improve alertness, which can be beneficial during a migraine episode.

Metoclopramide HCl is an antiemetic and prokinetic agent that addresses the nausea and vomiting often associated with migraines. By blocking dopamine receptors in the brain, Metoclopramide helps to prevent nausea and improve gastric motility, ensuring that the other active ingredients are absorbed more efficiently. This is particularly important in migraine treatment, as gastrointestinal stasis can impair drug absorption when taken orally.

The suppository form of this medication offers several advantages, particularly for patients who experience severe nausea and vomiting during migraines, which can make oral administration challenging. When inserted into the rectum, the suppository dissolves or melts, allowing the active ingredients to be absorbed through the rectal mucosa. This route of administration bypasses the gastrointestinal tract, providing a more direct and often faster onset of action, while also minimizing the risk of vomiting the medication.

For prescribers, this formulation offers a tailored approach to migraine management, combining vasoconstrictive, analgesic, and antiemetic properties in a single dosage form. It is important to consider the patient's overall health status, potential contraindications, and any concurrent medications when prescribing this treatment. Patients should be advised on the proper insertion technique for suppositories to ensure optimal absorption and efficacy.

If you have any questions about this formulation or its use, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide further information and support for both patients and healthcare providers.

The Ergotamine Tartrate 2 mg/Caffeine 100 mg/Metoclopramide HCl 10 mg suppositories are primarily formulated for the management of migraine headaches, particularly when oral administration is not feasible due to nausea or vomiting. However, this combination may have other potential uses that could be considered by healthcare providers based on their clinical judgment and patient-specific factors. The ergotamine component, known for its vasoconstrictive properties, may be explored for use in other types of vascular headaches or conditions where vasoconstriction is beneficial. Caffeine, aside from its role in enhancing the absorption and efficacy of ergotamine, may also provide additional analgesic effects and could be considered in scenarios where mild central nervous system stimulation is desired.

Metoclopramide, a prokinetic and antiemetic agent, is primarily included to address nausea and enhance gastrointestinal motility, which can be particularly beneficial in patients experiencing gastroparesis or other motility disorders. This could make the formulation useful in managing symptoms associated with delayed gastric emptying, where rectal administration bypasses the gastrointestinal tract, providing a direct route for systemic absorption. Additionally, the antiemetic properties of metoclopramide may be beneficial in other conditions characterized by severe nausea and vomiting, such as chemotherapy-induced nausea or postoperative nausea, where oral administration is not possible.

It is important for prescribers to consider the individual components of this formulation and their pharmacological actions when contemplating off-label uses. The rectal route of administration offers an alternative for patients who cannot tolerate oral medications, ensuring that the therapeutic effects of the active ingredients are still achieved. As with any off-label use, careful consideration of the patient's overall health status, potential drug interactions, and contraindications is essential. Patients should be informed about the intended use of the medication, potential side effects, and the importance of adhering to the prescribed regimen. If you have any questions or need further information, please reach out to us at Bayview Pharmacy.